Ozempic (semaglutide)

Novo Mike Doustdar 2
Pharma

Novo struggles to appease restless investors with new strategy

CEO Mike Doustdar acknowledged that the company’s leadership “have to convince” investors that “there is a bright future for Novo.”
Mike Doustdar

Novo CEO talks embracing change and staying bullish amid rebrand

Sep 17, 2026 8:45am
Doustdar

No more Nordisk as Novo goes it alone amid rebranding push

Sep 14, 2026 6:54am
Mounjaro

FDA approves Lilly's Mounjaro to reduce risk of cardio events

Aug 28, 2026 10:52am
Novo Nordisk Ozempic semaglutide

Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads

Jul 21, 2026 9:18am
Pause button

Dr. Reddy's temporarily pauses generic semaglutide supplies

Jul 9, 2026 8:48am